Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 2, Février 2003
Page(s) 201 - 210
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2003192201
Publié en ligne 15 février 2003
  1. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1996; 1287: 29–57.
  2. Mikkers H, Allen J, Knipscher P, et al. Highthroughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153–9.
  3. Lund AH, Turner G, Trubetskoy A, et al. Genome-wide retroviral tagging of genes involved in cancer in Cdkn2adeficient mice. Nat Genet 2002; 32: 160–5.
  4. Suszuki T, Shen H, Akagi K, et al. New genes involved in cancer identified by retrovirus tagging. Nat Genet 2002; 32: 166–74.
  5. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059–64
  6. Dalla-Favera R, Bregni M, Erikson J, et al. Human cmyc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824–7.
  7. Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plastocytoma cell. Proc Natl Acad Sci USA 1982; 79: 7837–41.
  8. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 1983; 306: 239–42.
  9. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143–9.
  10. Rabbitts TH. Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene 2001; 20: 5763–77.
  11. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia. Oncogene 2002; 21: 3422–44.
  12. Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002; 21: 3314–33.
  13. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002; 21: 3295–313
  14. Künstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerisation domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002; 22: 1513–25.
  15. Levy ER, Parganas E, Morishita K, et al. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood 1994; 83: 1348–53.
  16. Lallemand-Breitenbach V, Zhu J, de Thé H. La leucémie aiguë promyélocytaire: un paradigme des traitements ciblés sur l’oncogène? Med Sci 2001; 17 : 14–22.
  17. Poirel H, Bernard O. Implication des gènes du CBF dans la leucémogenèse. Hématologie 2000; 6 : 30–6.
  18. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–16.
  19. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nuclear protein gene, NPM in non-Hodgkin’s lymphoma. Science 1994; 263: 1281–4.
  20. Popovici C, Adélaïde J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in 210 stem cell myeloproliferative disorder with t(8;13) (p12;q12). Proc Natl Acad Sci USA 1998; 95: 5712–7.
  21. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosomeassociated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9) (p12;q33). Blood 2000; 95: 1788–96.
  22. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309–12.
  23. Kuno Y, Abe A, Emi N, et al. Constitutive activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12) (q22;p12). Blood 2001; 97: 1050–5.
  24. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukemia in children. Lancet 1999; 354: 1499–503.
  25. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002; 99: 8242–7.
  26. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. Bcl2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910–4.
  27. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–22.
  28. Pabst T, Meuller BU, Zhang P, et al. Dominant-negative mutations of mutations of C/EBPα, encoding CCAAT/enhancer binding protein alpha, in acute myeloid leukemia. Nat Genet 2001; 27: 263–70.
  29. Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332–40.
  30. Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci USA 2001; 98: 5776–9.
  31. Ma Z, Morris SW, Valentine V, et al. RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001; 28: 220–1.
  32. Shivadsani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965–73.
  33. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA 1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148–52.
  34. Song WJ, Sullivan MG, Legare RD, et al. Haploinsuffiency of CBFA2 (AML1) causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia (FPD/AML). Nat Genet 1999; 23: 166–75.
  35. Brown L, Cheng JT, Chen Q, et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 1990; 9: 3343–51.
  36. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multiple tumorsuppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87: 2180–6.
  37. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTENdeficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314–9.
  38. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98: 10320–5.
  39. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS- 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–6.
  40. Huettner CS, Zhang P, Van Etten RA, Tenen D. Reversibility of acute Bcell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57–60.
  41. Felsher DW, Bishop M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199–207.
  42. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7.
  43. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 5: 433–43.
  44. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002; 100: 585–93.
  45. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043–52.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.